secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0000950170-24-057429
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet presents ADI-270 preclinical data at ASGCT; IND filing expected Q2 2024
------------------------------------------------------------------------------

- ADI-270 is an allogeneic anti-CD70 CAR γδ T cell therapy for solid and hematological cancers.
- Preclinical data showed potent regression in ccRCC xenografts and lower CRS potential vs αβ CAR-T.
- Armoring includes TGFβ receptor II inactivation and protection against alloreactive T cells.
- IND submission in clear cell renal cell carcinoma (ccRCC) expected Q2 2024.
- ADI-270 demonstrated both CAR-dependent and CAR-independent tumor targeting mechanisms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024057429/0000950170-24-057429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024057429/acet-20240510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer